Transcriptomics: How to build a human
The manual for human development is written in the genetic code of our DNA. Our genes encode the instructions to make specific types of molecules that are needed to either build the human body or to control its day-to-day operations. The first step in producing these molecules involves the gene being copied, or transcribed, into an RNA molecule. For some genes, this RNA molecule is the end product; for other genes, the RNA molecule must then be translated to produce a protein.
Mistakes, or mutations, in a gene often change the RNA or protein produced, and even the smallest of changes can have far-reaching effects. For example, if these mutations affect molecules that are needed when a human embryo is developing in the womb, they can lead to severe abnormalities that are collectively called congenital disorders. A cleft palate is a relatively common example of a congenital disorder, and affects one in every 700 babies born each year (Forrester and Merz, 2004; Parker et al., 2010). Similarly, mutations that result in genes being active at the wrong time, or in the wrong cells in a developing embryo, can also lead to congenital disorders. In addition, exposure to toxic or infectious agents can also be a cause. This is exemplified by the drug thalidomide, which was administered to pregnant women between 1956 and 1962, and has caused severe birth defects in around 10,000 children worldwide (McBride, 1961).
Understanding why organs sometimes form incorrectly is challenging, largely because tissue from developing human embryos is rarely available for study. Instead, research has tended to extrapolate information from multiple sources, including individuals born with specific disorders, animal models and cell-based laboratory models of development and disease (Azamian and Lalani, 2016; Moretti et al., 2013; Kelly, 2016).
Some studies have investigated which genes are expressed in developing human embryos by looking at the RNA molecules produced at a given time. These “transcriptomics” studies, however, have tended to look at the embryo as a whole (Fang et al., 2010), or to focus on specific organs and tissues in more developed embryos (van den Berg et al., 2015; Slieker et al., 2015). Consequently, little was known about the formation and early development of organs – a process called organogenesis – in humans.
Over the past year or so, data on this crucial process has started to emerge. First, in mid-2015, a study described the transcriptional profiles of human embryos from different developmental stages (Roost et al., 2015). Now, in eLife, Neil Hanley and co-workers – from the University of Manchester and the Central Manchester University Hospitals NHS Foundation Trust – report transcriptomics data obtained during human organogenesis (Gerrard et al., 2016). The human embryonic material used in the study was collected according to the Codes of Practice of the UK Human Tissue Authority (HTA, 2016).
Hanley and co-workers – who include Dave Gerrard and Andrew Berry as joint first authors – looked at the RNA molecules found in organs and tissues from fifteen separate sites in human embryos. These sites included the thyroid, liver, stomach, brain, heart and adrenal gland. Gerrard et al. were then able to integrate this data into a sort of atlas that mapped the activity level of developmental genes across the embryo. This in turn allowed them to identify eleven groups of genes that were expressed differently in the different organs and tissues examined. Gerrard et al. refer to these groups of genes as metagenes and the activity levels of genes found in each metagene form a kind of transcriptional barcode for each of the different tissue types of the body.
Many cell-based models of development use stem cells from human embryos, or other cells that have been reprogrammed to be more like stem cells (so-called induced pluripotent stem cells; Takahashi et al., 2007). However, these approaches have their limitations (Hrvatin et al., 2014; Patterson et al., 2012), and it is challenging to ensure that stem cells differentiate into completely mature tissues in vitro. Gerrard et al. confirmed that the transcriptional barcode associated with the embryonic liver (metagene 2) was also seen in liver tissue derived from stem cells grown in the laboratory. This suggests that the transcriptional barcodes could be used to check that lab-grown stem cells have differentiated and matured as intended. Moreover, knowing which genes actively direct the cells in embryos to differentiate in specific ways could help other researchers to coax stem cells to become a wider range of tissues in vitro.
The work of Gerrard et al. adds substantially to what is known about the transcriptional profiles of each of the organs and tissues in a developing human embryo, and about the disorders associated with these tissues. Furthermore, their findings complement what we know about the later stages of embryonic development (Roost et al., 2015), and will allow a greater understanding of the distinct events that occur during human development and disease.
The findings by Hanley, Gerrard, Berry and colleagues have great implications for improving stem cell research. They will also undoubtedly aid research into diseases that develop at later stages of development, which has proved particularly challenging so far. Might we be on the cusp of completing the last pages of the ‘how to build a human’ manual? If so, soon we may finally be able to generate mature tissues more routinely in vitro and unravel the unknown mechanisms of development and disease.
References
-
Cytogenomic aberrations in congenital cardiovascular malformationsMolecular Syndromology 7:51–61.https://doi.org/10.1159/000445788
-
Transcriptome analysis of early organogenesis in human embryosDevelopmental Cell 19:174–184.https://doi.org/10.1016/j.devcel.2010.06.014
-
Descriptive epidemiology of oral clefts in a multiethnic population, Hawaii, 1986-2000The Cleft Palate-Craniofacial Journal 41:622–628.https://doi.org/10.1597/03-089.1
-
BookCardiac development and animal models of congenital heart defectsIn: S Rickert-Sperling, RG Kelly, DJ Driscoll, editors. Congenital Heart Diseases: The Broken Heart. Vienna: Springer. pp. 3–9.
-
Pluripotent stem cell models of human heart diseaseCold Spring Harbor Perspectives in Medicine 3:a014027.https://doi.org/10.1101/cshperspect.a014027
-
Updated national birth prevalence estimates for selected birth defects in the United States, 2004-2006Birth Defects Research Part A: Clinical and Molecular Teratology 88:1008–1016.https://doi.org/10.1002/bdra.20735
-
Defining the nature of human pluripotent stem cell progenyCell Research 22:178–193.https://doi.org/10.1038/cr.2011.133
-
DNA methylation landscapes of human fetal developmentPLOS Genetics 11:e1005583.https://doi.org/10.1371/journal.pgen.1005583
Article and author information
Author details
Publication history
Copyright
© 2016, Mellough et al.
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 2,027
- views
-
- 281
- downloads
-
- 1
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Further reading
-
- Developmental Biology
- Genetics and Genomics
The establishment and growth of the arterial endothelium requires the coordinated expression of numerous genes. However, regulation of this process is not yet fully understood. Here, we combined in silico analysis with transgenic mice and zebrafish models to characterize arterial-specific enhancers associated with eight key arterial identity genes (Acvrl1/Alk1, Cxcr4, Cxcl12, Efnb2, Gja4/Cx37, Gja5/Cx40, Nrp1 and Unc5b). Next, to elucidate the regulatory pathways upstream of arterial gene transcription, we investigated the transcription factors binding each arterial enhancer compared to a similar assessment of non-arterial endothelial enhancers. These results found that binding of SOXF and ETS factors was a common occurrence at both arterial and pan-endothelial enhancers, suggesting neither are sufficient to direct arterial specificity. Conversely, FOX motifs independent of ETS motifs were over-represented at arterial enhancers. Further, MEF2 and RBPJ binding was enriched but not ubiquitous at arterial enhancers, potentially linked to specific patterns of behaviour within the arterial endothelium. Lastly, there was no shared or arterial-specific signature for WNT-associated TCF/LEF, TGFβ/BMP-associated SMAD1/5 and SMAD2/3, shear stress-associated KLF4 or venous-enriched NR2F2. This cohort of well characterized and in vivo-verified enhancers can now provide a platform for future studies into the interaction of different transcriptional and signalling pathways with arterial gene expression.
-
- Developmental Biology
- Genetics and Genomics
Paternal obesity has been implicated in adult-onset metabolic disease in offspring. However, the molecular mechanisms driving these paternal effects and the developmental processes involved remain poorly understood. One underexplored possibility is the role of paternally induced effects on placenta development and function. To address this, we investigated paternal high-fat diet-induced obesity in relation to sperm histone H3 lysine 4 tri-methylation signatures, the placenta transcriptome, and cellular composition. C57BL6/J male mice were fed either a control or high-fat diet for 10 weeks beginning at 6 weeks of age. Males were timed-mated with control-fed C57BL6/J females to generate pregnancies, followed by collection of sperm, and placentas at embryonic day (E)14.5. Chromatin immunoprecipitation targeting histone H3 lysine 4 tri-methylation (H3K4me3) followed by sequencing (ChIP-seq) was performed on sperm to define obesity-associated changes in enrichment. Paternal obesity corresponded with altered sperm H3K4me3 at promoters of genes involved in metabolism and development. Notably, altered sperm H3K4me3 was also localized at placental enhancers. Bulk RNA-sequencing on placentas revealed paternal obesity-associated sex-specific changes in expression of genes involved in hypoxic processes such as angiogenesis, nutrient transport, and imprinted genes, with a subset of de-regulated genes showing changes in H3K4me3 in sperm at corresponding promoters. Paternal obesity was also linked to impaired placenta development; specifically, a deconvolution analysis revealed altered trophoblast cell lineage specification. These findings implicate paternal obesity effects on placenta development and function as one potential developmental route to offspring metabolic disease.